Veoza Approved for Use in England
Veoza (fezolinetant) has received approval for use on the NHS to prevent hot flushes in menopausal women, marking a significant advancement in treatment options for this common condition. The drug is particularly aimed at women for whom hormone replacement therapy (HRT) is unsuitable, providing a new avenue for relief.
Hot flushes affect approximately 70% of women undergoing menopause, leading to discomfort and a decline in quality of life. With around 500,000 women in England eligible for this treatment, the approval of Veoza is expected to have a substantial impact on those experiencing these symptoms.
The treatment is administered as a once-daily oral tablet, making it a convenient option for many. Veoza operates by blocking nerve pathways in the brain that trigger hot flushes and night sweats, addressing the root cause of these distressing symptoms.
The NHS has set the list price for Veoza at £44.80 per 28-tablet pack. This pricing was deemed cost-effective by the National Institute for Health and Care Excellence (NICE), which found that the drug offers value for taxpayers while providing essential relief to women.
Helen Knight, a representative from NICE, emphasized the importance of this approval, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added, “This decision will give much-needed relief to those for whom HRT is unsuitable.”
Dr. Sue Mann, a healthcare professional, echoed these sentiments, noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She further remarked, “It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health.”
Historically, there have been few safe and effective treatment options for menopausal hot flushes, leaving many women to cope with the discomfort without adequate support. The introduction of Veoza represents a significant shift in this landscape, offering hope to those affected.
As the healthcare community begins to implement this new treatment, observers are keen to see how it will be received by patients and whether it will meet the expectations set by its proponents. Details remain unconfirmed regarding the long-term effects and broader implications of widespread use of Veoza in the population.
You may also like
